Serum adipokines levels in patients with systemic sclerosis: A meta-analysis

Reference

• Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165–70.
   PubMed Web of Science ®Google Scholar
• Fett N. Scleroderma nomenclature, etiology, pathogenesis, prognosis, and treatments facts and controversies. Clin Dermatol. 2013;31(4):432–7.
   PubMed Web of Science ®Google Scholar
• Raja J, Denton CP. Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol. 2015;37(5):543–57.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.
   PubMed Web of Science ®Google Scholar
• Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002;16:22–6.
   PubMed Web of Science ®Google Scholar
• Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol. 2010;22:671–6.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003;301(4):1045–50.
   PubMed Web of Science ®Google Scholar
• Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34(1):2–11.
   PubMed Web of Science ®Google Scholar
• Procaccini C, Jirillo E, Matarese G. Leptin as an immunomodulator. Mol Aspects Med. 2012;33:35–45.
   PubMed Web of Science ®Google Scholar
• Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789–95.
   PubMed Web of Science ®Google Scholar
• Son YM, Ahn SM, Kim GR, Moon YS, Kim SH, Park YM, et al. Resistin enhances the expansion of regulatory T cells through modulation of dendritic cells. BMC Immunol. 2010;11:33.
   PubMed Web of Science ®Google Scholar
• Masui Y, Asano Y, Takahashi T, Shibata S, Akamata K, Aozasa N, et al. Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatol. 2013;23(2):323–9.
   PubMed Web of Science ®Google Scholar
• Winsz-Szczotka K, Kuźnik-Trocha K, Komosińska-Vassev K, Kucharz E, Kotulska A, Olczyk K. Relationship between adiponectin, leptin, IGF-1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. Int J Rheum Dis. 2014. [Epub ahead of print]. doi: 10.1111/1756-185X.12332.
   PubMed Web of Science ®Google Scholar
• Ozgen M, Koca SS, Isik B, Gundogdu B, Ustundag B, Isik A. Serum adiponectin and vaspin levels in systemic sclerosis. Turk J Biochem. 2011;36(1):35–42.
   Web of Science ®Google Scholar
• Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther. 2012;14(3):R102.
   PubMed Web of Science ®Google Scholar
• Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K, et al. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol. 2011;20(9):764–6.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of casecontrol studies in meta-analyses. Eur J Epidemiol. 2011;25:603–5.
   Web of Science ®Google Scholar
• Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, Teoh KH. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J. 2008;29(21):2592–600.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
   PubMed Web of Science ®Google Scholar
• Tomčík M, Arima K, Hulejová H, Kuklová M, Filková M, Braun M, et al. Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine. 2012;58(2):165–8.
   PubMed Web of Science ®Google Scholar
• Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, Batura-Gabryel H, Katulska K, Wojciech S, et al. Circulating adipokines and organ involvement in patients with systemic sclerosis. Acta Reumatol Port. 2015;40(2):156–62.
   PubMed Web of Science ®Google Scholar
• Masui Y, Asano Y, Shibata S, Noda S, Aozasa N, Akamata K, et al. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol. 2012;26(3):354–60.
   PubMed Web of Science ®Google Scholar
• Huertas A, Tu L, Gambaryan N, Girerd B, Perros F, Montani D, et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;40(4):895–904.
   PubMed Web of Science ®Google Scholar
• Atilgan ZA, Islamoglu Y, Tekbas E, Budulgan M, Batmaz I, Tahtasiz M, et al. Investigation of the effects of leptin on the cardiovascular system in patients with systemic sclerosis. Turk J Phys Med Rehab. 2013;59(4):319–24.
   Web of Science ®Google Scholar
• Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, et al. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis. 2012;15(4):374–9.
   PubMed Web of Science ®Google Scholar
• Budulgan M, Dilek B, Dağ ŞB, Batmaz I, Yıldız İ, Sarıyıldız MA, et al. Relationship between serum leptin level and disease activity in patients with systemic sclerosis. Clin Rheumatol. 2014;33(3):335–9.
   PubMed Web of Science ®Google Scholar
• Kotulska A, Kucharz EJ, Brzezińska-Wcisło L, Wadas U. A decreased serum leptin level in patients with systemic sclerosis. Clin Rheumatol. 2001;20(4):300–2.
   PubMed Web of Science ®Google Scholar
• Riccieri V, Stefanantoni K, Vasile M, Macrì V, Sciarra I, Iannace N, et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S46–52.
   PubMedGoogle Scholar
• Pischon T. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003;49:650–2.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15(1):1–10.
   PubMed Web of Science ®Google Scholar
• Šenolt L, Pavelka K, Housa D, Haluzík M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine. 2006;35:247–52.
   PubMed Web of Science ®Google Scholar
• Sada KE, Yamasaki Y, Maruyama M. Altered levels of adipocytokines in association with insulin resistance in patients with systemic lupus erythematosus. J Rheumatol. 2006; 33:1545–52.
   PubMed Web of Science ®Google Scholar
• Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raher MJ, et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol. 2009;41:397–406.
   PubMed Web of Science ®Google Scholar
• Dong Z, Su L, Esmaili S, Iseli TJ, Ramezani-Moghadam M, Hu L, et al. Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. J Mol Med (Berl). 2015;93(12):1327–39.
   PubMed Web of Science ®Google Scholar
• Yao R, Cao Y, He YR, Lau WB, Zeng Z, Liang ZA. Adiponectin attenuates lung fibroblasts activation and pulmonary fibrosis induced by paraquat. PLoS One. 2015;10(5):e0125169.
   PubMed Web of Science ®Google Scholar
• Fang F, Liu L, Yang Y, Tamaki Z, Wei J, Marangoni RG, et al. The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res Ther. 2012;14(5):R229.
   PubMed Web of Science ®Google Scholar
• Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005;579(2):295–301.
   PubMed Web of Science ®Google Scholar
• Tian G, Liang JN, Wang ZY, Zhou D. Emerging role of leptin in rheumatoid arthritis. Clin Exp Immunol. 2014;177(3):557–70.
   PubMed Web of Science ®Google Scholar
• Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab. 2015;26(3):153–61.
   PubMed Web of Science ®Google Scholar